IOVA Latest Headlines

Iovance posts ~$122M record quarter as Amtagvi demand lifts gross margin to ~60%

Market Chameleon (Thu, 5-Nov 7:19 AM)

Iovance Earnings Call Signals Strong AMTAGVI Momentum

at www.tipranks.com (Thu, 5-Nov 7:11 PM)

Iovance Biotherapeutics Updates Corporate Presentation Highlighting TIL Platform

at www.tipranks.com (Thu, 5-Nov 6:26 PM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Nuvectis Pharma (NVCT) and Pfizer (PFE)

at www.tipranks.com (Thu, 5-Nov 4:50 PM)

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Iovance Biotherapeutics (IOVA)

at www.tipranks.com (Thu, 5-Nov 2:00 PM)

Iovance Biotherapeutics GAAP EPS of -$0.05 beats by $0.04, revenue of $121.47M beats by $5.9M

at seekingalpha.com (Thu, 5-Nov 7:07 AM)

Iovance Biotherapeutics Q3 2026 Earnings Preview

at seekingalpha.com (Wed, 4-Nov 2:02 PM)

Iovance Biotherapeutics: Price Target Raised to $8, but Hold Maintained Amid Clinical and Launch Risks

at www.tipranks.com (Mon, 2-Nov 8:55 PM)

Strong Buy at under $10: The highest Quant-rated bargain stocks right now

at seekingalpha.com (Mon, 2-Nov 6:44 AM)

IOVA spotlights a 59.1% response subgroup as it tees up biomarker-enriched lung cancer enrollment in November 2026

Market Chameleon (Fri, 30-Oct 11:02 AM)

Iovance spotlights a 59.1% response-rate subgroup in metastatic non-squamous lung cancer trials

Market Chameleon (Thu, 29-Oct 7:08 AM)

Iovance spotlights 62.5% response rate for lifileucel plus pembrolizumab as Phase 3 frontline melanoma trial advances

Market Chameleon (Mon, 26-Oct 11:35 AM)

Iovance spotlights 50% response rate for lifileucel in early soft tissue sarcoma pilot as SARATOGA registrational trial enrolls

Market Chameleon (Mon, 26-Oct 7:07 AM)

Iovance brings lifileucel into new tumor types with first ESMO 2026 sarcoma oral data and frontline melanoma results

Market Chameleon (Mon, 19-Oct 7:35 AM)

Iovance lifts 2026 revenue outlook by $55 million at the midpoint as Amtagvi and Proleukin demand stays strong

Market Chameleon (Tue, 29-Sep 11:03 AM)

Iovance lifts 2026 revenue outlook by $55 million at the midpoint on strong U.S. demand for Amtagvi and Proleukin

Market Chameleon (Tue, 29-Sep 7:35 AM)

Iovance issues 179,750 inducement options at $10.02 to support new hires

Market Chameleon (Mon, 21-Sep 7:33 AM)

Iovance Awards Inducement Stock Options to New Hires as Pipeline and Commercial Reach Expand

Market Chameleon (Mon, 24-Aug 7:26 AM)